

The dynamics of FTO binding and demethylation from the m⁶A motifs

Yixing Li^{1#}, Kejing Wu^{2#}, Weili Quan^{2,3#}, Lin Yu¹, Shuang Chen³, Chao Cheng², Qijia Wu^{3†}, Shuhong Zhao⁴, Yi Zhang^{2,3*}, Lei Zhou^{1*}

¹State Key Laboratory for Conservation and Utilization of Subtropical Agro-bioresources, College of Animal Science and Technology, Guangxi University, Nanning, P.R. China

²Center for Genome Analysis, ABLife Inc., Wuhan, Hubei 430075, China.

³Laboratory for Genome Regulation and Human Health, ABLife Inc., Wuhan, Hubei 430075, China.

⁴Key Lab of Agricultural Animal Genetics and Breeding, Ministry of Education, College of Animal Science and Veterinary Medicine, Huazhong Agricultural University, Wuhan, 430070, P. R. China.

#These authors contributed equally to this work and were joint first authors.

***Corresponding author:**

Yi Zhang: yizhang@ablife.cc; Tel: 86-13317198317; Fax: 86-27-8177-9056

Lei Zhou: zhoulei@gxu.edu.cn; Tel: 86-771-3231158

[†]Present address: Healthiness Technology Co., Ltd. Building C2, No.666 Xiaoping Road, Wuhan East Lake High-tech Development Zone, Wuhan 430074, China.

ABSTRACT

*N*⁶-methyladenosine (m⁶A) is considered as a reversible RNA modification occurring more frequently on the GAC than AAC context *in vivo*, which regulates post-transcriptional gene expression in mammalian cells. m⁶A “writers” METTL3 and METTL14 demonstrate a strong preference for binding AC-containing motifs in living cells. However, this evidence is currently lacking for m⁶A erasers, leaving the dynamics of the internal m⁶A modification under debate recently. We analyzed three recently published FTO CLIP-seq data sets and two generated in this study, one of the two known m⁶A “erasers”. FTO binding peaks from all cell lines contain RRACH motifs. Only those from K562, 3T3-L1 and HeLa cells were enriched in AC-containing motifs, while those from HEK293 were not. The exogenously overexpressed FTO effectively binds to m⁶A motif-containing RNA sites. FTO overexpression specifically removed m⁶A modification from GGACU and RRACU motifs in a concentration-dependent manner. These findings underline the dynamics of FTO in target selection, which is predicted to contribute to both the m⁶A dynamics and the FTO plasticity in biological functions and diseases.

KEYWORDS: FTO; m⁶A; demethylases; RNA modification; CLIP-seq

Introduction

In early 1970s, several groups found that the methylation modification is not restricted to rRNAs and tRNAs, also occurs in polyadenylated cellular ^{1, 2} and viral ³⁻⁵ mRNAs. The methylated nucleosides in mRNAs were further determined as the 5'-terminal m⁷G(5')ppp(5')Nm ⁶⁻⁹ and the internal N⁶-methyl adenosine (m⁶A) ¹⁰⁻¹². The dimethylated nucleoside, N⁶, 2'-O-dimethyladenosine (m⁶Am), and the four common 2'-O-methylribonucleosides (Gm, Am, Um, Cm) at the second position were reported soon after ⁹. Then, internal m⁶A was reported to occur primarily in two sequence contexts, Gm⁶AC (70%) and Am⁶AC (30%) in HeLa cell ¹³, and 60% in Gm⁶AC in SV40 mRNA ¹⁴.

Recently, MeRIP-Seq (methylated RNA immunoprecipitation followed by sequencing) technology, also called m⁶A-seq, allows the mapping of m⁶A sites at the whole-transcriptome level ^{15, 16}. MeRIP-seq and a miCLIP-seq (m⁶A cross-linking) analysis confirmed that m⁶A modification preferably occurs within the consensus motif RRACH (R = G or A; H = A, C, or U), more in the sequence context of GAC than AAC ¹⁵⁻¹⁷. The currently published MeRIP-seq experiments commonly used a commercial antibody against both the internal m⁶A and the 5'-terminal m⁶Am ¹⁸⁻²⁰. miCLIP recovers mutation and truncations in cDNAs, which allows the mapping of about 18,000 high-confident cross-linking m⁶A sites among which a few hundred associates with the 5' terminal m⁶Am ¹⁷.

The RNA m⁶A modification is considered a reversible modification in living cells. The reversible m⁶A modification dictates the dynamics of m⁶A modification in

transcriptomes, which has been shown to regulate multiple processes of RNA metabolism, including alternative splicing, RNA stability and translation²¹⁻²⁷. Consistently, m⁶A modification modulates important biological processes, such as stem cell differentiation, heat shock response, oocyte competence and early zygotic development, neuronal and other development, and innate immunity^{24, 26, 28-31}, and is also involved in cancers³²⁻³⁸ and other diseases³⁹.

Nevertheless, a number of contradicting results have led to the current debate of the m⁶A dynamics⁴⁰⁻⁴⁴. m⁶A is added by RNA methyltransferase (“writer”) and removed by demethylases (“eraser”)^{23, 45}. Photoactivatable ribonucleoside-enhanced crosslinking and immunoprecipitation (PAR-CLIP) analysis has demonstrated that the binding peaks of methyltransferase METTL3 and METTL14 are highly enriched in RRACH motifs, consistent with a strong selection of the sequence context for their writing of m⁶A⁴⁶. So far, two RNA demethylases, fat mass and obesity-associated protein (FTO) and alkylated DNA repair protein AlkB homolog 5 (ALKBH5), have been identified to remove m⁶A modification^{39, 47}. However, neither of them has been shown to selectively bind to the internal m⁶A motifs. *In vitro* studies showed that neither FTO nor ALKBH5 shows strict dependence on RRACH motifs in their demethylation activity⁴⁸, although the sequence and structure of RNAs affect the demethylation activity of FTO⁴⁹. Three recently published works have performed FTO CLIP-seq experiments; however, none of them reports FTO binding of any m⁶A motifs⁵⁰⁻⁵². Moreover, a recent study showed that FTO could remove the methyl group from the 5'-cap m⁶Am with a much higher efficiency than that from the internal m⁶A⁵³. Therefore,

it remains highly questionable whether FTO recognizes and removes m⁶A from the internal m⁶A motifs, which is a key of the m⁶A reversibility and dynamics.

To investigate the FTO demethylation target sites in cells, we analyzed the published FTO CLIP data sets from human HEK293 cell line ⁵⁰, mouse embryonic fibroblasts (3T3-L1) ⁵¹, and FTO eCLIP data set from human erythroleukemia K562 cell line ⁵². FTO binding peaks from 3T3-L1 and K562 cells, but not from HEK293 cells, showed the presence of the GAC consensus in the top enriched motifs. We then performed FTO CLIP-seq in HeLa cells, showing that the GAC consensus was present in the top represented motifs. The m⁶A motifs were more enriched in FTO binding peaks upon its overexpression. We further showed that overexpression of FTO robustly removed m⁶A modification from RRACH motifs. Additionally, the number of transcripts subjected to FTO demethylation were increased with the FTO concentration. The cell type- and concentration-dependence of FTO binding and demethylation selectively from the internal m⁶A motifs support the m⁶A dynamics and reversibility.

Results

The m⁶A context GAC is enriched in FTO binding peaks from K562 and 3T3-L1 but not in HEK293T

To study whether FTO selectively binds to RRACH motif, we firstly analyzed three FTO CLIP/eCLIP data sets which were generated by three different labs from HEK293 ⁵⁰, K562 ⁵² and 3T3-L1 ⁵¹. The usable reads could estimate library complexity indicative of the binding strength of a RNA binding protein ⁵². FTO eCLIP-seq data contained significantly less usable reads than those of PTBP1 (K562), and much less in FTO

CLIP-seq data from HEK293 than that from K562 (Fig. S1a). This data profile could indicate a weak RNA binding affinity of FTO with its targets.

Plot of the distribution of FTO eCLIP/CLIP-seq reads and peaks showed a preferable location in the intronic region (Fig. S1b), consistent with its reported role in regulating alternative splicing^{24, 50}. When the regional distribution of CLIP/eCLIP reads was normalized by pre-mRNA length in each genic region, FTO-bound reads were enriched in 5'UTR in data sets from HEK293 and K562 (Fig. 1a). Consistent with the reported high efficiency of FTO demethylation of the 5'-end m⁶Am⁵³, a sharp enrichment of FTO binding signals around the transcription start site (TSS) was clearly demonstrated by all three replicates of CLIP-seq data from HEK293 cells, while the FTO binding signals were depleted around the stop codon (Fig. 1b). However, the TSS enrichment was not evident in the eCLIP-seq data from K562 cells, an enriched distribution across the entire 5'UTR was instead observed. Meanwhile, the depleted FTO binding at the stop codon and the 3' UTR region was seen, but to a much lesser extent than that of HEK293 (Fig. 1b). The distribution profile of FTO CLIP reads from 3T3-L1 around the TSS was between HEK293 and K562 (Fig. 1b).

We next identified FTO binding peaks using three different pipelines, Piranha⁵⁴, CIMS⁵⁵ and ABLIRC⁵⁶, all displaying similar peak distribution in different genomic regions (Fig. S1c). A *de novo* motif search of the 5-mer motifs from ABLIRC peaks using the HOMER algorithm revealed that the GAC- and/or GGAC-containing motifs were overrepresented in FTO binding peaks from K562, particularly in 3T3-L1, but not in those from HEK293T (Fig. 1c, and Fig. S2a). The search from CIMS peaks resulted

in the GGAC-containing overrepresented motif in one of K562 replicates, while no AC-containing motif was resulted from Piranha peaks from either K562 or HEK393 replicates (Fig. S2a). It should be noted that non-m⁶A FTO-binding motifs were different among cell lines. For example, GA-rich motifs and UUURA motif were more overrepresented than GAC and GGAC-motifs in K562 cells in both replicates, and GUUCG motif was highly overrepresented in HEK293T cells in three replicates, based on the motif resulted from ABLIRC peaks (Fig. S2a).

Given that the percentage of usable reads for the HEK293T cells was low, we randomly extracted 102,470 usable reads from each of all samples to call FTO binding peaks and then perform motif analysis. The results showed the that GAC and GGAC-motifs were enriched in FTO peaks from K562 and 3T3-L1 cells, but not in those from HEK293T cells (Fig. 1c, lower and Fig. S2b). Therefore, FTO binding of both m⁶A motifs and non-m⁶A motifs showed cell type-dependence.

FTO binds to GAC-containing and RRACH motifs in HeLa cells, and the exogenously overexpressed FTO shows increased selectivity.

As suggested above, FTO might not strongly associate with the internal m⁶A GAC motifs in some cell types. Theoretically, the increase of the cellular FTO concentrations would increase the concentration of FTO-target complex sensitive to CLIP-seq capture (Fig. 2a). To test this hypothesis, we overexpressed the Flag-tagged FTO excessively in HeLa cell line where the endogenous FTO expression level was low (Fig. S3a). Confocal fluorescence microscopy showed that FTO was localized both in nucleus and cytoplasm. When FTO was overexpressed, its localization in nucleus apparently

increased (Fig. S3b). The methylation level of total RNA and polyadenylated mRNA was then measured by dot blot analysis using antibody against both m⁶A and m⁶Am. It has been recently reported that the total amount of internal m⁶A is at least 10-fold larger than the amount of 5'-end m⁶Am in mRNAs, and FTO demethylates more m⁶A than m⁶Am in HeLa cells ^{49, 51}. FTO overexpression reduced the overall RNA methylation level as predicted, and a much more pronounced reduction was observed for total RNA than purified mRNA (Fig. S3c). This finding is in good agreement with the recent report that FTO has a higher preference to remove m⁶A from the primary transcript level ⁵⁷, and with the early findings of high m⁶A occurrence in 18S and 28S rRNAs ¹, as well as in tRNA ^{1, 19, 51}.

Under this functional context of FTO overexpression, we performed CLIP-seq experiments similar to eCLIP to identify FTO binding targets. To exclude the potential artifacts associated with a specific antibody, we used anti-FTO antibody in normal HeLa cells for two biological replicates and anti-Flag antibody in FTO-overexpressing (FTO-Flag) and control (Flag control) HeLa cells. Please be noted that in the CLIP-seq library construction approach applied here, the 5' adapter was ligated to the 5'-end of RNase-digested RNA after the end repair. This should eliminate the ligation to the 5'-end m⁶Am with a cap structure; only the FTO-bound m⁶Am-containing RNA fragments without a 5' cap structure could be recovered together with the internal m⁶A-containing RNA fragments. Both the FTO and Flag antibodies showed high specificity and efficiency in immunoprecipitation (Fig. S3d and S3e). The gel region containing protein-RNA complex above molecular weight of FTO and FTO-Flag was excised and

used for sequencing library preparation (Fig. S3f and Fig. S3g). A positive control CLIP library of PTBP1 was included. The data were summarized in Table S1.

We observed the similar low fraction of usable reads from FTO CLIP data in HeLa cells, while FTO overexpression increased the usable reads fraction (Fig. S4a). FTO CLIP tags in one replicate was highly accumulated near the FTO binding sites identified in the other biological replicate (Fig. S4b), demonstrating the confidence of the RNA binding activity of FTO. We further confirmed the specificity of the CLIP assay by performing UV-RIP-PCR analysis on a panel of anti-FTO enriched RNA fragments (Fig. S4d).

When compared with the enrichment in IgG controls, FTO CLIP reads did not enrich around the TSS nor 5'UTR region in normal HeLa cells (Fig. 2b, Fig. S4c). The overall FTO binding in transcribed regions were increased upon FTO overexpression (Fig. 2b, below). At the basal level of FTO expression, the majority of FTO binding peaks (46.43%-50.59%) were located in the intronic regions, similar as those of the previously published data (Fig. 2c, Fig S1c). When FTO was overexpressed in HeLa cells, the FTO binding peaks preferentially shifted to the protein coding regions (Fig. 2c).

Analysis of the 5-mer motifs showed that the most enriched motif harbored the GAC consensus sequence in both biological replicates of endogenous FTO binding sites (Fig. 2d and Fig. S4e). Upon FTO overexpression, motif enrichment scores increased consistent with the increased concentration of FTO-target RNA complex. Strikingly, the GAC-containing motif ranked as the most overrepresented one,

supporting that the exogenously expressed FTO was functional (Fig. 2d). When we increased the motif length during the motif search, the enrichment of GGAC and GGACU in top motifs appeared (Fig. S4f). We then calculated the fraction of FTO binding peaks containing GGACU motif and RRACH motifs in all the CLIP/eCLIP data. It is shown the peaks containing these m⁶A motifs were presented in all cell lines, although the frequency differed. FTO overexpression increased the m⁶A motif frequency in HeLa cells (Fig. 2e). Given that relative low percentage of usable reads for normal control (Fig. 4Sa), we randomly selected the same small number of usable reads as in Figure 1c (lower panel) from each sample to call FTO binding peaks and motif analysis. Similar results were obtained (Fig. S4g). These results confirmed that FTO binds to the m⁶A sequence context, and suggested that the binding is sensitive to the FTO concentration.

FTO overexpression effectively removes m⁶A modification from polyadenylated mRNA/lncRNAs at GGACU motifs in HeLa cells

Given that the overexpressed FTO-Flag bound to GGACU motif in HeLa cells, we then explored whether FTO-Flag could remove m⁶A from this typical m⁶A motifs, by performing m⁶A-seq experiments to capture m⁶A sites on polyadenylated mRNAs/lncRNAs in control (Flag-control) and FTO-overexpression (FTO-Flag) HeLa cells. The sequence data from two different benches of experiments was shown, with 22.2-fold (H) and 4.3-fold (L) of FTO overexpression by comparing the FPKM values of FTO in the corresponding input controls (Table S2, Fig.3a). Analysis of the input controls showed that the expression level of key m⁶A writer and eraser genes was not

changed upon FTO overexpression, which eliminated the complication of the result interpretation (Fig. 3a).

Analysis of the distribution of all mapped reads revealed that 96.5%-99.7% of input and m⁶A-seq reads of each sample were mapped to nuclear encoded protein genes, pseudogenes and long non-coding RNAs (Table S3), which supported the purity of mRNAs used in this study. For the following peak calling and motif analysis, only uniquely mapped reads were involved, which removed any remaining complication from tRNAs and rRNAs. We called m⁶A peaks from m⁶A-seq data by running ABLIRC pipeline and MACS, followed by a *de novo* motif search with the HOMER algorithm, using input reads as backgrounds. Motif analysis showed that in control cells (Flag-control), the most significantly enriched motifs in m⁶A-bound peaks in both replicates were characterized by GGACU consensus sequence, which exactly matched the canonical m⁶A motif (Fig. 3b). Consistent with the hypothesis that FTO demethylates from its bound m⁶A motif, GGACU motif disappeared from the top-ranking motifs in FTO-overexpressed cells (Fig. 3b and Fig. S5a).

Calculating the ratio of RRACU-bearing peaks in all m⁶A peaks confirmed the majority of peaks (52.90%~ 61.36%) detected in Flag-control cells contained RRACU motif, which reduced significantly (33.97%~36.91%) upon FTO overexpression (Fig. 3c). Additionally, the frequency of RRACU at the m⁶A peak positions in FTO overexpressed cells was substantially lower than that observed at Flag-control cells (Fig. S5b). These results are all in line with the conclusion that FTO selectively erases

the m⁶A modification from the RRACU motif of polyadenylated mRNAs/lncRNAs, likely in a FTO concentration-sensitive manner.

To further study the FTO selectivity of RRACU motif for its “eraser” function, we separated the m⁶A peaks into two groups by either containing or lacking a RRACU motif. We then plotted the m⁶A-seq reads around the center of these m⁶A peaks. In accordance with the m⁶A-demethylation activity of FTO, we observed a substantial decreased amount of m⁶A-seq reads around the center of peak containing RRACU motif after FTO overexpression, in both sets of the experiments (Fig. 3d, upper and Fig. S5c, left). In contrast, around the center of peaks lacking the RRACU consensus sequence, the level of m⁶A-seq reads was not decreased, but somewhat increased upon FTO overexpression (Fig. 3d, upper and Fig. S5c, right)

As examples, FTO specifically removed m⁶A signals from the RRACU-containing peaks in 3' UTRs of the apoptosis associated gene *DFFA*⁵⁸ and lipid metabolism genes *PPARD* and *VLDLR*^{59, 60} (Fig. 3e and Fig. S6), which contained the GGACU motif. It is possible that FTO regulates body mass index and obesity, partially by specifically removing the m⁶A modification from *PPARD* and *VLDLR*. We also showed examples whose m⁶A levels were not decreased by FTO, and these m⁶A modification occurred at RRACU-lacking peaks. These included m⁶A clusters on the internal exons of the splicing factor *SFPQ* (Fig. 3e) and *RPL23A* (Fig. S6) and one cluster in the intronic region of *ZNF701* (Fig. S6).

We further validated the dependence of RRACU motif for FTO demethylation by RIP-qRT-PCR. Consistent with our findings above, all but one RRACU-bearing m⁶A

259 sites showed decreased m⁶A signals upon FTO overexpression, whereas all of those
260 lacking RRACU motif showed unchanged or increased m⁶A levels upon FTO
261 overexpression (Fig. 3f). Taken together, overexpressed FTO preferentially removed
262 m⁶A modification from the GGACU motif.

263 **The extent of FTO demethylation from mRNAs/lncRNAs is concentration-** 264 **dependent**

265 FTO selection of RRACH motif for m⁶A demethylation in HeLa cells might represent a
266 unique mechanism for FTO specificity in demethylating a population of genes but not
267 the other. We noticed the m⁶A peak calling approach was not sensitive to the genes
268 with high mRNA level. For example, we found that FTO specifically removed m⁶A
269 modification from activating transcription factor ATF4 mRNA (Fig. 4a), a recently
270 reported FTO target⁶¹. One m⁶A modification being removed was well correlated with
271 the reported alternative translation site controlled by m⁶A dynamics (Fig. 4a). However,
272 these m⁶A modifications were not recovered by peak calling pipelines, due to the high
273 input signals.

274 We therefore subjected m⁶A-seq reads to the edgeR software to identify
275 differentially methylated genes (DMG) associated with FTO overexpression. For both
276 benches of overexpression experiments, a much larger number of DMGs were down-
277 methylated compared with those up-methylated. We showed the down-methylated
278 genes were 5,872 and 2030 and the up-methylated genes were 1679 and 893, for the
279 22.2-fold and 4.3-fold FTO overexpression, respectively (Fig. 4b). As control, the
280 difference between the corresponding input samples was very small (Fig. 4b). The

extent of FTO demethylation of mRNA/lncRNAs was apparently concentration-dependent (Fig. 3c and Fig. S5b).

We further showed that m⁶A peak-containing genes from the control Flag samples were more significantly overlapped with the FTO down-demethylated genes, than those from samples with FTO overexpression (Fig. 4c). This further supported that the FTO demethylation occurs at the m⁶A-modified transcripts.

Discussion

The presented results together support a model for the dynamics of FTO in mediating m⁶A demethylation. FTO binds to GAC-containing and RRACH motifs in mRNAs/lncRNAs typical for m⁶A modification in a cell type-dependent manner. FTO binds to m⁶A motifs and removes the m⁶A modification in a concentration-dependent manner in HeLa cells. This model supports the m⁶A dynamics and diverse regulatory functions, and provides mechanistic insights into the FTO plasticity in biological functions and its reported involvement in multiple diseases.

This is the first report showing that FTO recognizes and binds to m⁶A motifs in cells, which is similar to the two m⁶A “writers” methyltransferases METTL3 and METTL14⁴⁶. Therefore, in contrast to non-selectively of the demethylation activity of two ‘eraser’ proteins FTO and ALKBH5 *in vitro*⁴⁸, our results demonstrated that the selectively of FTO binding and demethylation from m⁶A motifs in living cells. In fact, a recent *in vitro* studies showed both the tertiary structure and sequence of the RNA substrates can affect the catalytic activity of FTO⁴⁹. Our results are consistent with the recent findings

of the specific targets of FTO and ALKBH5 involved in diverse biological functions ³⁵,
^{37, 61-63}.

We have showed that FTO binds mRNA/lncRNA towards GAC-containing and
RRACH motifs in multiple cell lines, with its motif selectivity being cell-type dependent.
The association between FTO and m⁶A motifs is enhanced by FTO overexpression,
and the overexpressed FTO preferentially removes m⁶A modification from GGACU and
RRACU motifs also in a concentration-dependent manner, at least in HeLa cells. We
propose that the concentration-dependence of FTO action shall contribute to the
observed m⁶A/m⁶Am dynamics and enable a larger regulatory plasticity of m⁶A/m⁶Am
mark under different physiological and pathological states. Given the structural and
functional similarity between FTO and ALKBH5, it could be possible that ALKBH5 also
contacts with the internal m⁶A similarly.

The finding of FTO binding and demethylation from the internal m⁶A motifs might
reconciliate some of the recent conflicted results. For example, Mauer *et al.* showed
that FTO controls mRNA stability in HEK293T cells with its demethylation activity
towards m⁶Am ⁵³. Results from the other two groups showed certain contradiction ⁵¹,
⁶⁴, which add the debate in this field. In one study, FTO demethylation on internal m⁶A
has a greater effect on mRNA stability than the ones with cap m⁶Am in the tested cells
⁵¹. In the other study, m⁶Am promotes the translation of capped mRNAs, but not
stabilize A-starting capped mRNAs ⁶⁴. In the context of the findings presented in this
study, the discrepancy might be resulted from the different FTO expression levels and
cell lines among these studies. In fact, one of these two studies demonstrates that the

efficiency of FTO in demethylating m⁶A and m⁶Am is distinct among different cell lines, which depends on the relative levels of m⁶A/m⁶Am and the nucleus and cytoplasm distribution of FTO protein ⁵¹.

Additionally, our analysis showed that FTO binding was mostly enriched at the TSS region in HEK293 cells, although the CLIP-seq method applied to obtain the data disfavor the recovery of FTO-bound m⁶Am-containing RNA fragments with an intact 5' cap ⁵⁰. This finding is well correlated with the previously reported high preference of FTO for m⁶Am as a substrate ⁵³, if we assume that at least a fraction of the TSS binding signals of FTO represents its demethylation of m⁶Am. The more preferred distribution of FTO binding sites in the 5'UTR and 3'UTR body regions of K562 and HeLa cells is consistent with the reported functions and the m⁶A profiles regulated by FTO in other leukemia cells and mouse embryonic fibroblasts ^{34, 37}. We suggest that the cell type-dependent binding of FTO, a potential indicator of its demethylation target selection, should be taken into account in explaining data in the future studies.

In conclusion, we have demonstrated the selectivity of FTO in binding and erasing m⁶A modification from m⁶A motifs, which support FTO functions in regulating the dynamics and distribution of m⁶A/m⁶Am mark under different physiological and pathological states ^{26, 34, 37, 50, 51, 65-68}. We propose that FTO-mRNA/lncRNA association is weak, which leaves rooms for additional cellular factors to corporately work with this eraser to choose among the internal m⁶A sites and 5'-end m⁶Am in different transcripts. The dynamics of FTO in target selection is predicted to be sensitive to physiological and pathological changes, and contribute to both m⁶A dynamics and the FTO plasticity

in biological functions and its reported involvement in multiple diseases. Further study of the FTO dynamics and m⁶A/m⁶Am demethylation regulation should be critical for m⁶A biology and the related disease control.

Materials and methods

Cell culture, Plasmid and transfection

HeLa cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) (Gibco) supplemented with 10% fetal bovine serum (FBS) (Hyclone) and 1% penicillin/streptomycin (Hyclone) at 37 °C in a humidified incubator with 5% CO₂.

The cDNA of human FTO gene (GenBank: NM_001080432.2) amplified by PCR and subcloned into pCMV-Tag.2B-Flag vector (Stratagene). pCMV-Tag.2B-Flag vector containing FTO gene (FTO-Flag) or not containing FTO gene (Flag-control) were transfected into HeLa cells using Lipofectamine 2000 (Invitrogen, 11668-027) following manufacturer's instructions.

Western blots

Total protein lysate was extracted from FTO overexpression/control cells with RIPA buffer. 40-60 µg protein extracts were separated by SDS-PAGE and transferred to PVDF membranes (Bio-Rad, cat. 1620177, Foster, California, USA). Membranes were blocked with 5% non-fat milk, followed by overnight incubation with primary antibodies against either FTO (CUSABIO, Shanghai) or Flag (Sigma, cat. F7425) overnight at R.T. After the incubation with Rhodamine (TRITC) goat anti-rabbit IgG (Abclonal, cat.

A5040) (1: 10,000) for 1 hour at R.T, the signals were detected with Clarity Max™ Western ECL Substrate (Bio-Rad, cat. 1705062).

Immunofluorescence analysis

After washed with PBS, HeLa was fixed in 4% formaldehyde. Cells were blocked in 5% BSA in PBS with 0.2% Triton X-100 for 10 min. Cells were incubated with antibody against FTO (MBL, RN121PW) overnight at 4 °C. After washing with PBS, cells were incubated with an anti-rabbit IgG (Abclonal, cat. A5040) (1:100) in the dark at R.T for 1 hour. DAPI staining for DNA was performed. Images were obtained using a confocal LSM780 microscope (Carl Zeiss, Germany).

CLIP-seq

HeLa cells (~10⁶) cultured to a confluence of 70-80% with or without FTO-Flag or Flag transfection were subjected to UV cross-linking treatment on ice for 400 mJ/cm². The cross-linked cells were then lysed and treated with RQ1 RNase-Free DNase (Progema, cat. M6101) to prevent DNA contamination, followed by partially digestion with MNase (Thermo, cat. EN0181) to further release the FTO-protected RNA fragments in a FTO-RNA complex form. FTO-RNA complex was immunoprecipitated by incubating with DynaBeads protein A/G conjugated with anti-FTO antibody (MBL, cat. RN121PW, Japan), IgG (Millipore, cat. 12-370, USA) or anti-Flag antibody (sigma, cat. F7425, USA) at 4 °C for 2 hours. Efficiency of the immunoprecipitation of was showed in Fig. S3. RNA was dephosphorylated at 3' end and phosphorylated at 5' end. The protein-RNA complex was separated by 4-12% NuPAGE Bis-Tris gel (Nvirogen, cat. NP0321 BOX) and the region of the membrane 30 kDa above the protein size was excised (Fig.

S3e). Protein was digested by proteinase K and RNA was isolated to prepare sequencing library using Balancer sm/miRNA Library Preparation Kit according to the manufacturer's instructions (Gnomegen, cat. K02420). The cDNA libraries were subsequently quantified and sequenced on the Illumina Nextseq platform. Image processing and base-calling were performed by Illumina pipeline.

Analysis of CLIP-seq data

The clean reads were generated from raw sequencing reads after removing adaptor sequences and low quality sequences, which were mapped to human GRCh38 genome using Tophat (v2.1.1). Reads aligned to more than one genome location were discarded. 'Usable' reads were defined as reads that uniquely mapped to the genome and remained after discarding PCR duplicates.

FTO CLIP-seq peaks were identified by running Piranha,⁵⁴ CIMS⁵⁵ and ABLIRC.⁵⁶ The target genes of FTO were finally determined by analyzing the genomic locations of all the FTO binding peaks. A *de novo* motif search with the HOMER algorithm⁶⁹ was performed to identify FTO binding sites.

UV-RIP-qPCR

HeLa cells (~10⁶) were UV cross-linked, which were operated similarly as CLIP-seq described above to obtain the cross-linked protein-RNA complex right after immunoprecipitation, without further treatment. MNase was not used to further fragment RNA associated with FTO. Then, RNA was purified from the protein-RNA complex by proteinase K treatment, phenol/chloroform extraction and precipitated with ethanol. The isolated FTO-associated RNA was reverse transcribed using random

primer, and analyzed by quantitative, strand-specific RT-PCR using the Real-time detection system using a QuantStudio 6 Flex System (ABI). Gene-specific PCR primer pairs were presented in Table S4.

m⁶A dot blot assay

Total RNA was extracted using TRIzol Reagent (Ambion) following the manufacturer's instructions, and mRNA were then purified by GenElute™ mRNA Miniprep Kit (sigma, MRN10). The m⁶A-dot-blot was performed on the Bio-Dot® Microfiltration Apparatus (170-6545, GE Healthcare) using Amersham Hybond-N+ membrane (GE Amersham, RPN303B) in two-fold dilutions. After UV crosslinking, the blotted membrane was washed by 1×PBST buffer, blocked with 5% of non-fat milk, and incubated with primary rabbit anti-m⁶A antibody (sysy, cat. 202003) overnight at 4 °C. After incubated with Horseradish peroxidase (HRP)-conjugated anti-rabbit IgG (DakoCytomation, p0448) secondary antibody, the membrane was visualized by supersignal westPico ECL substrate box (Thermo Pierce, 34087).

m⁶A immunoprecipitation and m⁶A-seq

The polyadenylated mRNAs isolated from total RNA using GenElute™ mRNA Miniprep Kit (sigma, MRN10) were fragmented into 100 nt length by using RNA Fragmentation buffer (0.1M Tris-HCL PH 7.0, 0.1M ZnCl₂). Then, 50 and 100 ng fragmented mRNAs were incubated for 2 hours at 4 °C with 12.5 µg of anti-m⁶A antibody (sysy, 202003) in IP buffer (0.05M Tris-HCL pH 7.4, 0.375M NaCl, 0.5% Igepal CA-630). The mixture was then subjected to immunoprecipitation by incubation with Pierce™ ChIP-grade Protein A/G Magnetic Beads (Thermo, 26162) at 4 °C for 2 hours. After sufficient

washing, m⁶A antibody-bound RNA was eluted from the beads with Elution buffer (1×IP buffer, 7mM m⁶A, RNase inhibitor), and then ethanol-precipitated. The eluted RNA was resuspended in H₂O and used to generate the cDNA library according to RNA-Seq Library Preparation Kit for Transcriptome Discovery–Illumina Compatible, which was then sequenced using the HiSeq 2000 system (Illumina) according to the manufacturer's instructions.

Analysis of m⁶A_seq data

For m⁶A-Seq data, adaptors and low quality bases were trimmed from raw sequencing reads using CutAdapt, and reads less than 16nt were discarded. After quality control and data filtering, reads were aligned to the reference genome GRCh38 by TopHat2 (v2.1.1). To assess m⁶A level of each gene, only reads unambiguously aligned were preserved to calculate reads number and RPKM value (RPKM represents reads per kilobase and per million). To identify the m⁶A regions (statistically significant m⁶A peaks), we called m⁶A peaks from m⁶A-seq data by running ABLIRC pipeline ⁵⁶.

m⁶A-qRT-PCR

m⁶A immunoprecipitation was performed as above. The ethanol-precipitated m⁶A antibody-bound RNA fragments were reverse transcribed using random primer, and then subjected to quantitative, strand-specific RT-PCR using the Real-time detection system using a QuantStudio 6 Flex System (ABI). Gene-specific PCR primer pairs were presented in Table S5.

Differentially demethylated genes (DMG)

Differentially demethylated genes between the paired groups were analyzed by using edgeR in R packages⁴. For each gene, significance p-value was obtained based on the model of negative binomial distribution. Fold changes of gene expression were also estimated within the edgeR statistical package. The criterion for DMG has been set as fold change >2 or <0.5 and $P < 0.01$.

Statistical analysis

For the comparison of proportions of m⁶A peaks with or without the RRACU motif and the qPCR results, statistical analyses were carried out using Student's t-test. The results of qPCR are shown as the mean \pm SE. Statistical analysis was performed using R (v3.1.3).

Data availability

All CLIP-seq and m⁶A-seq data from this study have been submitted to the NCBI Gene Expression Omnibus (GEO; <http://www.ncbi.nlm.nih.gov/geo/>) under accession number GSE101955. PTB CLIP data are available at NCBI with BioProject ID: PRJNA377229 (<https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA377229>). A link to a UCSC genome browser session displaying the uploaded sequence tracks has been created (https://genome.ucsc.edu/cgi-bin/hgTracks?hgS_doOtherUser=submit&hgS_otherUserName=erhuoyi&hgS_otherUserSessionName=fto).

Acknowledgements

We are grateful to Yaqiang Xue, and Yali Ye (ABLife) for their contributions to the experimental parts, and to Yaxun Wei (ABLife) in helping some graphics. This work

was supported by the grants from National Key R&D Program of China (2018YFD0500402), National Natural Science Foundation of China (31660641), Guangxi Natural Science Foundation (2017GXNSFAA198139), Guangxi Hundred-Talent Program, State Key Laboratory for Conservation and Utilization of Subtropical Agro-bioresources (SKLCUSA-a201808), and Scientific Research Foundation of Guangxi University (XTZ130719). This study is also supported by grant from ABLife Inc. (ABL2013-07002).

Disclosure of Interest

No potential conflict of interest was reported by the authors.

REFERENCES

1. Desrosiers R, Friderici K, Rottman F. Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells. *Proc Natl Acad Sci U S A* 1974; 71:3971-5.
2. Perry RP, Kelley DE. Existence of methylated messenger RNA in mouse L cells. *Cell* 1974; 1:37-42.
3. Furuichi Y. "Methylation-coupled" transcription by virus-associated transcriptase of cytoplasmic polyhedrosis virus containing double-stranded RNA. *Nucleic Acids Res* 1974; 1:809-22.
4. Rhodes DP, Moyer SA, Banerjee AK. In vitro synthesis of methylated messenger RNA by the virion-associated RNA polymerase of vesicular stomatitis virus. *Cell* 1974; 3:327-33.
5. Shatkin AJ. Methylated messenger RNA synthesis *in vitro* by purified reovirus. *Proc Natl Acad Sci U S A* 1974; 71:3204-7.
6. Abraham G, Rhodes DP, Banerjee AK. The 5' terminal structure of the methylated mRNA synthesized in vitro by vesicular stomatitis virus. *Cell* 1975; 5:51-8.
7. Furuichi Y, Miura K-I. A blocked structure at the 5' terminus of mRNA from cytoplasmic polyhedrosis virus. *Nature* 1975; 253:374.
8. Furuichi Y, Morgan M, Muthukrishnan S, Shatkin AJ. Reovirus messenger RNA contains a methylated, blocked 5'-terminal structure: m-7G(5')ppp(5')G-MpCp. *Proc Natl Acad Sci U S A* 1975; 72:362-6.
9. Wei CM, Gershowitz A, Moss B. 5'-Terminal and internal methylated nucleotide

508 sequences in HeLa cell mRNA. *Biochemistry* 1976; 15:397-401.

509 10. Adams JM, Cory S. Modified nucleosides and bizarre 5'-termini in mouse myeloma
510 mRNA. *Nature* 1975; 255:28-33.

511 11. Furuichi Y, Morgan M, Shatkin AJ, Jelinek W, Salditt-Georgieff M, Darnell JE.
512 Methylated, blocked 5' termini in HeLa cell mRNA. *Proc Natl Acad Sci U S A* 1975;
513 72:1904-8.

514 12. Wei C, Gershowitz A, Moss B. N⁶, O^{2'}-dimethyladenosine a novel methylated
515 ribonucleoside next to the 5' terminal of animal cell and virus mRNAs. *Nature* 1975;
516 257:251-3.

517 13. Wei CM, Moss B. Nucleotide sequences at the N⁶-methyladenosine sites of HeLa
518 cell messenger ribonucleic acid. *Biochemistry* 1977; 16:1672-6.

519 14. Canaani D, Kahana C, Lavi S, Groner Y. Identification and mapping of N⁶-
520 methyladenosine containing sequences in simian virus 40 RNA. *Nucleic Acids Res*
521 1979; 6:2879-99.

522 15. Meyer KD, Saletore Y, Zumbo P, Elemento O, Mason CE, Jaffrey SR.
523 Comprehensive analysis of mRNA methylation reveals enrichment in 3' UTRs and near
524 stop codons. *Cell* 2012; 149:1635-46.

525 16. Dominissini D, Moshitch-Moshkovitz S, Schwartz S, Salmon-Divon M, Ungar L,
526 Osenberg S, et al. Topology of the human and mouse m⁶A RNA methylomes revealed
527 by m⁶A-seq. *Nature* 2012; 485:201-6.

528 17. Linder B, Grozhik AV, Olarerin-George AO, Meydan C, Mason CE, Jaffrey SR.
529 Single-nucleotide-resolution mapping of m⁶A and m⁶Am throughout the transcriptome.

530 Nat Methods 2015; 12:767-72.

531 18. Jia G, Fu Y, Zhao X, Dai Q, Zheng G, Yang Y, et al. N6-methyladenosine in nuclear
532 RNA is a major substrate of the obesity-associated FTO. Nat Chem Biol 2011; 7:885-
533 7.

534 19. Munns TW, Liszewski MK, Sims HF. Characterization of antibodies specific for N6-
535 methyladenosine and for 7-methylguanosine. Biochemistry 1977; 16:2163-8.

536 20. Bringmann P, Luhrmann R. Antibodies specific for N⁶-methyladenosine react with
537 intact snRNPs U2 and U4/U6. FEBS Lett 1987; 213:309-15.

538 21. Fu Y, Jia G, Pang X, Wang RN, Wang X, Li CJ, et al. FTO-mediated formation of
539 N⁶-hydroxymethyladenosine and N⁶-formyladenosine in mammalian RNA. Nat
540 commun 2013; 4:1798.

541 22. Wang X, Lu Z, Gomez A, Hon GC, Yue Y, Han D, et al. N⁶-methyladenosine-
542 dependent regulation of messenger RNA stability. Nature 2013; 505:117-20.

543 23. Meyer KD, Jaffrey SR. The dynamic epitranscriptome: N⁶-methyladenosine and
544 gene expression control. Nat Rev Mol Cell Biol 2014; 15:313-26.

545 24. Zhao X, Yang Y, Sun BF, Shi Y, Yang X, Xiao W, et al. FTO-dependent
546 demethylation of N6-methyladenosine regulates mRNA splicing and is required for
547 adipogenesis. Cell Res 2014; 24:1403-19.

548 25. Meyer Kate D, Patil Deepak P, Zhou J, Zinoviev A, Skabkin Maxim A, Elemento O,
549 et al. 5' UTR m⁶A promotes cap-independent translation. Cell 2015; 163:999-1010.

550 26. Zhou J, Wan J, Gao X, Zhang X, Jaffrey SR, Qian SB. Dynamic m⁶A mRNA
551 methylation directs translational control of heat shock response. Nature 2015;

552 526:591-4.

553 27. Yang Y, Fan X, Mao M, Song X, Wu P, Zhang Y, et al. Extensive translation of
554 circular RNAs driven by N⁶-methyladenosine. *Cell Res* 2017; 27:626-41.

555 28. Zheng Q, Hou J, Zhou Y, Li Z, Cao X. The RNA helicase DDX46 inhibits innate
556 immunity by entrapping m⁶A-demethylated antiviral transcripts in the nucleus. *Nat*
557 *Immunol* 2017; 18:1094-103.

558 29. Chen T, Hao YJ, Zhang Y, Li MM, Wang M, Han W, et al. m⁶A RNA methylation is
559 regulated by microRNAs and promotes reprogramming to pluripotency. *Cell Stem Cell*
560 2015; 16:289-301.

561 30. Haussmann IU, Bodi Z, Sanchez-Moran E, Mongan NP, Archer N, Fray RG, et al.
562 m⁶A potentiates Sxl alternative pre-mRNA splicing for robust *Drosophila* sex
563 determination. *Nature* 2016; 540:301-4.

564 31. Ivanova I, Much C, Di Giacomo M, Azzi C, Morgan M, Moreira PN, et al. The RNA
565 m⁶A reader YTHDF2 is essential for the post-transcriptional regulation of the maternal
566 transcriptome and oocyte competence. *Mol Cell* 2017; 67:1-9.

567 32. Liu J, Eckert MA, Harada BT, Liu S-M, Lu Z, Yu K, et al. m⁶A mRNA methylation
568 regulates AKT activity to promote the proliferation and tumorigenicity of endometrial
569 cancer. *Nat Cell Biol* 2018; 20:1074-83.

570 33. Chen M, Wei L, Law CT, Tsang FH, Shen J, Cheng CL, et al. RNA N⁶-
571 methyladenosine methyltransferase-like 3 promotes liver cancer progression through
572 YTHDF2-dependent posttranscriptional silencing of SOCS2. *Hepatology* 2018;
573 67:2254-70.

- 574 34. Li Z, Weng H, Su R, Weng X, Zuo Z, Li C, et al. FTO plays an oncogenic role in
575 acute myeloid leukemia as a N⁶-methyladenosine RNA demethylase. *Cancer Cell* 2017;
576 31:127-41.
- 577 35. Cui Q, Shi H, Ye P, Li L, Qu Q, Sun G, et al. m⁶A RNA methylation regulates the
578 self-renewal and tumorigenesis of glioblastoma stem cells. *Cell Rep* 2017; 18:2622-
579 34.
- 580 36. Barbieri I, Tzelepis K, Pandolfini L, Shi J, Millan-Zambrano G, Robson SC, et al.
581 Promoter-bound METTL3 maintains myeloid leukaemia by m⁶A-dependent translation
582 control. *Nature* 2017; 552:126-31.
- 583 37. Su R, Dong L, Li C, Nachtergaele S, Wunderlich M, Qing Y, et al. R-2HG exhibits
584 anti-tumor activity by targeting FTO/m⁶A/MYC/CEBPA signaling. *Cell* 2018; 172:1-16.
- 585 38. Zhang C, Samanta D, Lu H, Bullen JW, Zhang H, Chen I, et al. Hypoxia induces
586 the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m⁶A-
587 demethylation of NANOG mRNA. *Proc Natl Acad Sci U S A* 2016; 113:E2047-E56.
- 588 39. Zheng G, Dahl JA, Niu Y, Fedorcsak P, Huang C-M, Li Charles J, et al. ALKBH5 is
589 a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. *Mol*
590 *Cell* 2013; 49:18-29.
- 591 40. Zhao BS, Nachtergaele S, Roundtree IA, He C. Our views of dynamic N⁶-
592 methyladenosine RNA methylation. *RNA* 2018; 24:268-72.
- 593 41. Mauer J, Jaffrey SR. FTO, m⁶Am, and the hypothesis of reversible
594 epitranscriptomic mRNA modifications. *FEBS Lett* 2018; 592:2012-22.
- 595 42. Darnell RB, Ke S, Darnell JE. Pre-mRNA processing includes N⁶ methylation of

596 adenosine residues that are retained in mRNA exons and the fallacy of “RNA
597 epigenetics”. *RNA* 2018; 24:262-7.

598 43. Rosa-Mercado NA, Withers JB, Steitz JA. Settling the m⁶A debate: methylation of
599 mature mRNA is not dynamic but accelerates turnover. *Genes Dev* 2017; 31:957-8.

600 44. Meyer KD, Jaffrey SR. Rethinking m⁶A readers, writers, and erasers. *Annu Rev*
601 *Cell Dev Biol* 2017; 33:319-42.

602 45. Fu Y, Dominissini D, Rechavi G, He C. Gene expression regulation mediated
603 through reversible m⁶A RNA methylation. *Nat Rev Genet* 2014; 15:293-306.

604 46. Liu J, Yue Y, Han D, Wang X, Fu Y, Zhang L, et al. A METTL3-METTL14 complex
605 mediates mammalian nuclear RNA N⁶-adenosine methylation. *Nat Chem Biol* 2014;
606 10:93-5.

607 47. Huang Y, Yan J, Li Q, Li J, Gong S, Zhou H, et al. Meclofenamic acid selectively
608 inhibits FTO demethylation of m⁶A over ALKBH5. *Nucleic Acids Res* 2015; 43:373-84.

609 48. Zou S, Toh JD, Wong KH, Gao YG, Hong W, Woon EC. N⁶-Methyladenosine: a
610 conformational marker that regulates the substrate specificity of human demethylases
611 FTO and ALKBH5. *Sci Rep* 2016; 6:25677.

612 49. Zhang X, Wei LH, Wang Y, Xiao Y, Liu J, Zhang W, et al. Structural insights into
613 FTO's catalytic mechanism for the demethylation of multiple RNA substrates. *Proc Natl*
614 *Acad Sci U S A* 2019; 116:2919-24.

615 50. Bartosovic M, Molares HC, Gregorova P, Hrossova D, Kudla G, Vanacova S. N⁶-
616 methyladenosine demethylase FTO targets pre-mRNAs and regulates alternative
617 splicing and 3'-end processing. *Nucleic Acids Res* 2017; 45:11356-70.

618 51. Wei J, Liu F, Lu Z, Fei Q, Ai Y, He PC, et al. Differential m⁶A, m⁶Am, and m¹A
619 demethylation mediated by FTO in the cell nucleus and cytoplasm. *Mol Cell* 2018;
620 71:973-85.

621 52. Van Nostrand EL, Pratt GA, Shishkin AA, Gelboin-Burkhart C, Fang MY,
622 Sundararaman B, et al. Robust transcriptome-wide discovery of RNA-binding protein
623 binding sites with enhanced CLIP (eCLIP). *Nat Methods* 2016; 13:508-14.

624 53. Mauer J, Luo X, Blanjoie A, Jiao X, Grozhik AV, Patil DP, et al. Reversible
625 methylation of m⁶Am in the 5' cap controls mRNA stability. *Nature* 2017; 541:371-5.

626 54. Uren PJ, Bahrami-Samani E, Burns SC, Qiao M, Karginov FV, Hodges E, et al.
627 Site identification in high-throughput RNA-protein interaction data. *Bioinformatics* 2012;
628 28:3013-20.

629 55. Moore MJ, Zhang C, Gantman EC, Mele A, Darnell JC, Darnell RB. Mapping
630 Argonaute and conventional RNA-binding protein interactions with RNA at single-
631 nucleotide resolution using HITS-CLIP and CIMS analysis. *Nat Protoc* 2014; 9:263-93.

632 56. Xia H, Chen D, Wu Q, Wu G, Zhou Y, Zhang Y, et al. CELF1 preferentially binds
633 to exon-intron boundary and regulates alternative splicing in HeLa cells. *Biochim*
634 *Biophys Acta* 2017; 1860:911-21.

635 57. Ke S, Pandya-Jones A, Saito Y, Fak JJ, Vagbo CB, Geula S, et al. m⁶A mRNA
636 modifications are deposited in nascent pre-mRNA and are not required for splicing but
637 do specify cytoplasmic turnover. *Genes Dev* 2017; 31:990-1006.

638 58. Liu X, Zou H, Slaughter C, Wang X. DFF, a heterodimeric protein that functions
639 downstream of caspase-3 to trigger DNA fragmentation during apoptosis. *Cell* 1997;

640 89:175-84.

641 59. Seedorf U, Aberle J. Emerging roles of PPAR δ in metabolism. *Biochim Biophys*
642 *Acta* 2007; 1771:1125-31.

643 60. Tacke PJ, Hofker MH, Havekes LM, van Dijk KW. Living up to a name: the role
644 of the VLDL receptor in lipid metabolism. *Curr Opin Lipidol* 2001; 12:275-9.

645 61. Zhou J, Wan J, Shu XE, Mao Y, Liu X-M, Yuan X, et al. N⁶-methyladenosine guides
646 mRNA alternative translation during integrated stress response. *Mol Cell* 2018; 69:1-
647 12.

648 62. Zhang S, Zhao BS, Zhou A, Lin K, Zheng S, Lu Z, et al. m⁶A demethylase ALKBH5
649 maintains tumorigenicity of glioblastoma stem-like cells by sustaining FOXM1
650 expression and cell proliferation program. *Cancer Cell* 2017; 31:591-606.

651 63. Zhang S-Y, Zhang S-W, Liu L, Meng J, Huang Y. m⁶A-driver: identifying context-
652 specific mRNA m⁶A methylation-driven gene interaction networks. *PLoS Comp Biol*
653 2016; 12:e1005287.

654 64. Akichika S, Hirano S, Shichino Y, Suzuki T, Nishimasu H, Ishitani R, et al. Cap-
655 specific terminal N⁶-methylation of RNA by an RNA polymerase II-associated
656 methyltransferase. *Science* 2018:eaav0080.

657 65. Shun Z, Zhou - Lan B, Di X, Zhi - Jun Z, Ren Z, Yan - Yang W, et al. FTO
658 regulates the chemo - radiotherapy resistance of cervical squamous cell carcinoma
659 (CSCC) by targeting β -catenin through mRNA demethylation. *Mol Carcinog* 2018;
660 57:590-7.

661 66. Mathiyalagan P, Adamiak M, Mayourian J, Sassi Y, Liang Y, Agarwal N, et al. FTO-

662 dependent m6A regulates cardiac function during remodeling and repair. *Circulation*
663 2018.

664 67. Engel M, Eggert C, Kaplick PM, Eder M, Röh S, Tietze L, et al. The role of m⁶A/m-
665 RNA methylation in stress response regulation. *Neuron* 2018; 99:389-403.

666 68. Xiang Y, Laurent B, Hsu CH, Nachtergaele S, Lu Z, Sheng W, et al. RNA m⁶A
667 methylation regulates the ultraviolet-induced DNA damage response. *Nature* 2017;
668 543:573-6.

669 69. Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, et al. Simple
670 Combinations of Lineage-Determining Transcription Factors Prime cis-Regulatory
671 Elements Required for Macrophage and B Cell Identities. *Mol Cell* 2010; 38:576-89.

672

673

Figures




Fig. 1




Fig. 2




Fig. 3




Fig. 4

Figure captions

Figure 1 Transcriptome-wide landscape of FTO binding shows cell type-

specificity. Three recently published FTO eCLIP/CLIP-seq data were analyzed.

(a) FTO-binding reads were enriched in 5'UTR in HEK293 and K562, but not 3T3-L1 cells. CLIP/eCLIP reads mapped to each region of genome was normalized by the length of the region. There is no replicate and input control for 3T3-L1 cell, a suggested RNA-seq data was analyzed as input control. The enrichment of each region was calculated relative to CDS region. Nc_exon, non-coding exon.

(b) Enrichment of FTO binding around the transcription start site (TSS) and stop codons was different among HEK293, K562 and 3T3-L1 cells. Normalized FTO binding reads count (RPM) in a ± 1000 bp window around TSS (left) and stop codons (right) for all transcripts. RPM, reads per million.

(c) GAC-containing motifs were enriched in K562 and 3T3-L1, but not in HEK293 cells. The 5-nt FTO binding motifs were detected from ABLIRC peaks by HOMER. Those from one sample were presented, and all others were shown in Fig. S2. Motifs include GAC-consensus were marked with a black box. Original usable reads (upper) and randomly selected same number (102,470) of usable reads (lower) were used for peak calling and the motif analysis, respectively.

Figure 2 FTO selectively binds to m⁶A motifs in HeLa cells, and the exogenously overexpressed FTO shows higher selectivity.

(a) A model shows the proposed dynamics of reactions forming FTO-RRACH and FTO-RRA(m⁶A)CH that could be captured by anti-FTO immunoprecipitation.

(b) FTO CLIP reads were not enriched around the TSS or 5'UTR region compared to IgG control in normal HeLa cells (upper panel), but were enriched in all transcribed regions when captured the overexpressed Flag-FTO (lower panel). Normalized FTO binding reads count in a ± 1000 bp window around TSS (left) and stop codons (right) for CLIP-seq data. FTO_1 and FTO_2, and IgG_1 and IgG_2, represent two replicated CLIP-seq data obtained from normal HeLa cells using anti-FTO and anti-IgG antibodies, respectively. FTO_Flag represents CLIP-seq data obtained from HeLa cells transfected with plasmid expressing FTO-Flag fusion protein, and Flag represents that from the control HeLa cells transfected with Flag-only plasmid. RPM, reads per million.

(c) FTO binding were increased in the protein coding regions upon overexpression. Genomic distribution of FTO binding reads (left) and peaks (right) in HeLa cells.

(d) The top FTO binding motifs detected by HOMER.

(e) The fractions of FTO binding peaks containing GGACU and RRACH motifs were different among 3T3-L1, HEK293T, K562 and HeLa cells. The overexpressed FTO shows higher fractions of GGACU and RRACH-containing peaks in HeLa cells.

Figure 3 m⁶A demethylation by FTO is RRACU-dependent in HeLa cells.

(a) FTO overexpression did not affect the expression of other m⁶A writers and erasers in m⁶A-seq input samples, which were polyadenylated RNAs. FTO-H and FTO-L represent samples from HeLa cells with high-fold (22.2) or low-fold (4.3) FTO overexpression in relative to the Flag-control, respectively. Normalized FPKM values of each gene was presented.

(b) GGACU motif was the top first motif in m⁶A peaks from control HeLa cells, which was disappeared upon FTO overexpression.

(c) Relative proportions of m⁶A peaks with or without RRACU motifs. RRACU-bearing m⁶A peaks were detected in a higher frequency in Flag-control cells than that in FTO-Flag cells with FTO overexpression ($P < 0.05$). The P values were determined using Student's unpaired t test. FTO-H and FTO-L were regarded as replicates.

(d) Metagene distribution of m⁶A-seq reads around the center of m⁶A peaks identified in Flag-control cells. m⁶A peaks were divided into two groups according to the presence or absence of the RRACU motif.

(e) Examples of FTO demethylation from mRNA transcripts at the m⁶A peak containing a RRACU motif (DFFA), but not at the m⁶A peak lacking a RRACU motif (SFPQ) in HeLa cells. The m⁶A read density as shown for each gene in reads per million (RPM). Each gene was diagrammed by vertical black bars (exons) and thin horizontal lines (introns). m⁶A peak regions were shadowed by light green rectangles and arrow.

(f) m⁶A qRT-PCR validation of the RRACU-dependence in FTO demethylation of m⁶A.

The *P* values were determined using Student's unpaired *t* test. * *P* < 0.05. ** *P* < 0.01.

*** *P* < 0.001. Results are shown as mean ± SE.

Figure 4 The extent of FTO demethylation is concentration-dependent.

(a) FTO-mediated demethylation of m⁶A in gene ATF4 is concentration-dependence.

FTO-demethylated regions were marked with black box.

(b) The number of genes whose mRNA/lncRNA methylation levels were down-

regulated by FTO overexpression were 2.3-3.5 folds of the up-regulated, and

increased with FTO levels. The number of up-regulated and down-regulated DMGs

were showed in bar plot.

(c) FTO down-methylated genes are significantly overlapped with the m⁶A peak genes

in both high-fold and low-fold FTO overexpression samples. The *p* values indicated

statistical significance of the number of overlapping genes.